New oral drugs for erectile dysfunction
Relevant BNF section: 7.4.5
In 1998, we concluded that sildenafil (Viagra - Pfizer Ltd), a selective phosphodiesterase type 5 inhibitor, appeared to offer advantages over other medical approaches for erectile dysfunction in terms of ease of administration and cost.1 Oral drug treatment is now widely advocated as first-line therapy for erectile dysfunction,2 except where the cause is clearly psychological. In the past 4 years, three more oral preparations have been licensed in the UK for the treatment of men with erectile dysfunction. A sublingual preparation of the dopaminergic agonist 
apomorphine (Uprima - Abbott Laboratories Ltd) is the first centrally acting drug to be licensed. Tadalafil (Cialis - Eli-Lilly) and vardenafil (Levitra - Bayer PLC) are phosphodiesterase type 5 inhibitors. Here we review the place of these preparations for men with erectile dysfunction.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
